@2024 - All Right Reserved.

Urology consultation: MRI of a male pelvis showing the bladder and the prostate. Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and ...

Men with aggressive prostate cancer, often left with few options after chemotherapy fails, now have access to a new treatment that uses a radioactive substance.The new treatment, Lutetium-177 PSMA ...

Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). Alicia Morgans, MD: I am curious from ...

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer ...

Greater radiotracer uptake on PSMA-PET is associated with an increased likelihood of achieving a PSA decline in response to lutetium-177. The finding is from a study of 97 patients with mCRPC treated ...

Association of radiomic skeletal muscle features on prostate T1-weighted MRI with major adverse cardiac events in prostate cancer patients. This is an ASCO Meeting Abstract from the 2026 ASCO ...

or on the link below. ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid ...

Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this video, Tanya Dorff, MD, head of the ...